HEADER SUGAR BINDING PROTEIN 12-DEC-17 6F83 TITLE CRYSTAL STRUCTURE OF HUMAN GALECTIN-1 IN COMPLEX WITH THIENYL-1,2, 3- TITLE 2 TRIAZOLYL THIODIGALACTOSIDE INHIBITOR COMPND MOL_ID: 1; COMPND 2 MOLECULE: GALECTIN-1; COMPND 3 CHAIN: A, B; COMPND 4 SYNONYM: GAL-1,14 KDA LAMININ-BINDING PROTEIN,HLBP14,14 KDA LECTIN, COMPND 5 BETA-GALACTOSIDE-BINDING LECTIN L-14-I,GALAPTIN,HBL,HPL,LACTOSE- COMPND 6 BINDING LECTIN 1,LECTIN GALACTOSIDE-BINDING SOLUBLE 1,PUTATIVE MAPK- COMPND 7 ACTIVATING PROTEIN PM12,S-LAC LECTIN 1; COMPND 8 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: LGALS1; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI BL21(DE3); SOURCE 7 EXPRESSION_SYSTEM_TAXID: 469008; SOURCE 8 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 9 EXPRESSION_SYSTEM_PLASMID: PET3A KEYWDS CARBOHYDRATE-RECOGNITION, BETA SANDWICH, CARBOHYDRATE BINDING KEYWDS 2 PROTEIN, SUGAR BINDING PROTEIN EXPDTA X-RAY DIFFRACTION AUTHOR P.M.COLLINS,H.BLANCHARD REVDAT 2 17-JAN-24 6F83 1 REMARK REVDAT 1 30-JAN-19 6F83 0 JRNL AUTH A.PETERSON,P.M.COLLINS,B.KAHL-KNUTSSON,F.R.ZETTERBERG, JRNL AUTH 2 H.BLANCHARD,H.LEFFLER,U.J.NILSSON JRNL TITL AROMATIC HETEROCYCLE GALECTIN-1 INTERACTIONS FOR SELECTIVE JRNL TITL 2 SINGLE-DIGIT NM AFFINITY LIGANDS JRNL REF TO BE PUBLISHED JRNL REFN REMARK 2 REMARK 2 RESOLUTION. 2.20 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : REFMAC REMARK 3 AUTHORS : MURSHUDOV,SKUBAK,LEBEDEV,PANNU,STEINER, REMARK 3 : NICHOLLS,WINN,LONG,VAGIN REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.20 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 56.18 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 91.7 REMARK 3 NUMBER OF REFLECTIONS : 13558 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.174 REMARK 3 R VALUE (WORKING SET) : 0.171 REMARK 3 FREE R VALUE : 0.224 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.000 REMARK 3 FREE R VALUE TEST SET COUNT : 712 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 2090 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 82 REMARK 3 SOLVENT ATOMS : 77 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : 32.06 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 1.78000 REMARK 3 B22 (A**2) : -1.91000 REMARK 3 B33 (A**2) : 0.13000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED OVERALL COORDINATE ERROR. REMARK 3 ESU BASED ON R VALUE (A): 0.289 REMARK 3 ESU BASED ON FREE R VALUE (A): 0.213 REMARK 3 ESU BASED ON MAXIMUM LIKELIHOOD (A): 0.152 REMARK 3 ESU FOR B VALUES BASED ON MAXIMUM LIKELIHOOD (A**2): 12.537 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 DISTANCE RESTRAINTS. RMS SIGMA REMARK 3 BOND LENGTH (A) : NULL ; NULL REMARK 3 ANGLE DISTANCE (A) : NULL ; NULL REMARK 3 INTRAPLANAR 1-4 DISTANCE (A) : NULL ; NULL REMARK 3 H-BOND OR METAL COORDINATION (A) : NULL ; NULL REMARK 3 REMARK 3 PLANE RESTRAINT (A) : NULL ; NULL REMARK 3 CHIRAL-CENTER RESTRAINT (A**3) : NULL ; NULL REMARK 3 REMARK 3 NON-BONDED CONTACT RESTRAINTS. REMARK 3 SINGLE TORSION (A) : NULL ; NULL REMARK 3 MULTIPLE TORSION (A) : NULL ; NULL REMARK 3 H-BOND (X...Y) (A) : NULL ; NULL REMARK 3 H-BOND (X-H...Y) (A) : NULL ; NULL REMARK 3 REMARK 3 CONFORMATIONAL TORSION ANGLE RESTRAINTS. REMARK 3 SPECIFIED (DEGREES) : NULL ; NULL REMARK 3 PLANAR (DEGREES) : NULL ; NULL REMARK 3 STAGGERED (DEGREES) : NULL ; NULL REMARK 3 TRANSVERSE (DEGREES) : NULL ; NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: U VALUES : WITH TLS ADDED HYDROGENS REMARK 3 HAVE BEEN USED IF PRESENT IN THE INPUT REMARK 4 REMARK 4 6F83 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 12-DEC-17. REMARK 100 THE DEPOSITION ID IS D_1200007913. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 30-JUL-09 REMARK 200 TEMPERATURE (KELVIN) : 293 REMARK 200 PH : 6.2 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : N REMARK 200 RADIATION SOURCE : ROTATING ANODE REMARK 200 BEAMLINE : NULL REMARK 200 X-RAY GENERATOR MODEL : MACSCIENCE REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.5418 REMARK 200 MONOCHROMATOR : OSMIC MIRRORS REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : BRUKER SMART 6000 REMARK 200 INTENSITY-INTEGRATION SOFTWARE : PROTEUM PLUS REMARK 200 DATA SCALING SOFTWARE : SCALA 3.3.20 REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 14295 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.199 REMARK 200 RESOLUTION RANGE LOW (A) : 56.180 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 92.0 REMARK 200 DATA REDUNDANCY : 2.900 REMARK 200 R MERGE (I) : NULL REMARK 200 R SYM (I) : 0.06400 REMARK 200 FOR THE DATA SET : 12.0000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.20 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.32 REMARK 200 COMPLETENESS FOR SHELL (%) : 63.0 REMARK 200 DATA REDUNDANCY IN SHELL : 1.70 REMARK 200 R MERGE FOR SHELL (I) : 0.44200 REMARK 200 R SYM FOR SHELL (I) : 0.44200 REMARK 200 FOR SHELL : 1.800 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: FOURIER SYNTHESIS REMARK 200 SOFTWARE USED: REFMAC REMARK 200 STARTING MODEL: 3OYW REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 49.70 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.45 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 4-8 MICROLITRE DROPS CONSISTING OF REMARK 280 EQUAL VOLUMES OF PROTEIN SOLUTION (20 MM SODIUM POTASSIUM REMARK 280 PHOSPHATE BUFFER, PH 7.0, AND PROTEIN AT CONCENTRATION OF 10 MG/ REMARK 280 ML) AND RESERVOIR SOLUTION (0.2 M AMMONIUM SULPHATE, 25% W/V REMARK 280 POLYETHYLENE GLYCOL 4000, 0.1M SODIUM ACETATE TRIHYDRATE, PH 6.2) REMARK 280 , VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 293K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 22.22350 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 56.17650 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 29.34450 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 56.17650 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 22.22350 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 29.34450 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 1150 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 12550 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -5.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ASP A 37 -176.84 -174.39 REMARK 500 ASN A 56 55.79 39.42 REMARK 500 ASN B 56 62.82 39.68 REMARK 500 PRO B 78 31.23 -89.61 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue 5KT A 201 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue 5KT B 201 DBREF 6F83 A 1 134 UNP P09382 LEG1_HUMAN 2 135 DBREF 6F83 B 1 134 UNP P09382 LEG1_HUMAN 2 135 SEQRES 1 A 134 ALA CYS GLY LEU VAL ALA SER ASN LEU ASN LEU LYS PRO SEQRES 2 A 134 GLY GLU CME LEU ARG VAL ARG GLY GLU VAL ALA PRO ASP SEQRES 3 A 134 ALA LYS SER PHE VAL LEU ASN LEU GLY LYS ASP SER ASN SEQRES 4 A 134 ASN LEU CME LEU HIS PHE ASN PRO ARG PHE ASN ALA HIS SEQRES 5 A 134 GLY ASP ALA ASN THR ILE VAL CME ASN SER LYS ASP GLY SEQRES 6 A 134 GLY ALA TRP GLY THR GLU GLN ARG GLU ALA VAL PHE PRO SEQRES 7 A 134 PHE GLN PRO GLY SER VAL ALA GLU VAL CME ILE THR PHE SEQRES 8 A 134 ASP GLN ALA ASN LEU THR VAL LYS LEU PRO ASP GLY TYR SEQRES 9 A 134 GLU PHE LYS PHE PRO ASN ARG LEU ASN LEU GLU ALA ILE SEQRES 10 A 134 ASN TYR MET ALA ALA ASP GLY ASP PHE LYS ILE LYS CME SEQRES 11 A 134 VAL ALA PHE ASP SEQRES 1 B 134 ALA CYS GLY LEU VAL ALA SER ASN LEU ASN LEU LYS PRO SEQRES 2 B 134 GLY GLU CME LEU ARG VAL ARG GLY GLU VAL ALA PRO ASP SEQRES 3 B 134 ALA LYS SER PHE VAL LEU ASN LEU GLY LYS ASP SER ASN SEQRES 4 B 134 ASN LEU CME LEU HIS PHE ASN PRO ARG PHE ASN ALA HIS SEQRES 5 B 134 GLY ASP ALA ASN THR ILE VAL CME ASN SER LYS ASP GLY SEQRES 6 B 134 GLY ALA TRP GLY THR GLU GLN ARG GLU ALA VAL PHE PRO SEQRES 7 B 134 PHE GLN PRO GLY SER VAL ALA GLU VAL CME ILE THR PHE SEQRES 8 B 134 ASP GLN ALA ASN LEU THR VAL LYS LEU PRO ASP GLY TYR SEQRES 9 B 134 GLU PHE LYS PHE PRO ASN ARG LEU ASN LEU GLU ALA ILE SEQRES 10 B 134 ASN TYR MET ALA ALA ASP GLY ASP PHE LYS ILE LYS CME SEQRES 11 B 134 VAL ALA PHE ASP MODRES 6F83 CME A 16 CYS MODIFIED RESIDUE MODRES 6F83 CME A 42 CYS MODIFIED RESIDUE MODRES 6F83 CME A 60 CYS MODIFIED RESIDUE MODRES 6F83 CME A 88 CYS MODIFIED RESIDUE MODRES 6F83 CME A 130 CYS MODIFIED RESIDUE MODRES 6F83 CME B 16 CYS MODIFIED RESIDUE MODRES 6F83 CME B 42 CYS MODIFIED RESIDUE MODRES 6F83 CME B 60 CYS MODIFIED RESIDUE MODRES 6F83 CME B 88 CYS MODIFIED RESIDUE MODRES 6F83 CME B 130 CYS MODIFIED RESIDUE HET CME A 16 10 HET CME A 42 10 HET CME A 60 10 HET CME A 88 10 HET CME A 130 10 HET CME B 16 10 HET CME B 42 10 HET CME B 60 10 HET CME B 88 10 HET CME B 130 10 HET 5KT A 201 41 HET 5KT B 201 41 HETNAM CME S,S-(2-HYDROXYETHYL)THIOCYSTEINE HETNAM 5KT 3-DEOXY-3-[4-(THIOPHEN-3-YL)-1H-1,2,3-TRIAZOL-1-YL]- HETNAM 2 5KT BETA-D-GALACTOPYRANOSYL 3-DEOXY-1-THIO-3-[4-(THIOPHEN- HETNAM 3 5KT 3-YL)-1H-1,2,3-TRIAZOL-1-YL]-BETA-D-GALACTOPYRANOSIDE FORMUL 1 CME 10(C5 H11 N O3 S2) FORMUL 3 5KT 2(C24 H28 N6 O8 S3) FORMUL 5 HOH *77(H2 O) HELIX 1 AA1 PRO A 101 GLY A 103 5 3 SHEET 1 AA112 ALA A 67 TRP A 68 0 SHEET 2 AA112 ASP A 54 ASP A 64 -1 N ASP A 64 O ALA A 67 SHEET 3 AA112 ASN A 40 ALA A 51 -1 N ASN A 46 O VAL A 59 SHEET 4 AA112 PHE A 30 ASP A 37 -1 N LEU A 34 O LEU A 43 SHEET 5 AA112 ILE A 117 GLY A 124 -1 O ALA A 121 N ASN A 33 SHEET 6 AA112 VAL A 5 LEU A 11 -1 N ALA A 6 O MET A 120 SHEET 7 AA112 VAL B 5 LEU B 11 -1 O VAL B 5 N SER A 7 SHEET 8 AA112 ILE B 117 GLY B 124 -1 O MET B 120 N ALA B 6 SHEET 9 AA112 PHE B 30 ASP B 37 -1 N ASN B 33 O ALA B 121 SHEET 10 AA112 ASN B 40 ALA B 51 -1 O LEU B 43 N LEU B 34 SHEET 11 AA112 ASP B 54 ASP B 64 -1 O ASN B 61 N HIS B 44 SHEET 12 AA112 ALA B 67 TRP B 68 -1 O ALA B 67 N ASP B 64 SHEET 1 AA212 GLN A 72 GLU A 74 0 SHEET 2 AA212 ASP A 54 ASP A 64 -1 N CME A 60 O GLN A 72 SHEET 3 AA212 ASN A 40 ALA A 51 -1 N ASN A 46 O VAL A 59 SHEET 4 AA212 PHE A 30 ASP A 37 -1 N LEU A 34 O LEU A 43 SHEET 5 AA212 ILE A 117 GLY A 124 -1 O ALA A 121 N ASN A 33 SHEET 6 AA212 VAL A 5 LEU A 11 -1 N ALA A 6 O MET A 120 SHEET 7 AA212 VAL B 5 LEU B 11 -1 O VAL B 5 N SER A 7 SHEET 8 AA212 ILE B 117 GLY B 124 -1 O MET B 120 N ALA B 6 SHEET 9 AA212 PHE B 30 ASP B 37 -1 N ASN B 33 O ALA B 121 SHEET 10 AA212 ASN B 40 ALA B 51 -1 O LEU B 43 N LEU B 34 SHEET 11 AA212 ASP B 54 ASP B 64 -1 O ASN B 61 N HIS B 44 SHEET 12 AA212 GLN B 72 GLU B 74 -1 O GLN B 72 N CME B 60 SHEET 1 AA310 GLU A 105 PRO A 109 0 SHEET 2 AA310 ASN A 95 LYS A 99 -1 N LEU A 96 O PHE A 108 SHEET 3 AA310 VAL A 84 PHE A 91 -1 N CME A 88 O LYS A 99 SHEET 4 AA310 CME A 16 VAL A 23 -1 N LEU A 17 O ILE A 89 SHEET 5 AA310 PHE A 126 ASP A 134 -1 O CME A 130 N ARG A 20 SHEET 6 AA310 PHE B 126 PHE B 133 -1 O LYS B 129 N PHE A 133 SHEET 7 AA310 LEU B 17 VAL B 23 -1 N ARG B 20 O LYS B 129 SHEET 8 AA310 VAL B 84 PHE B 91 -1 O ILE B 89 N LEU B 17 SHEET 9 AA310 ASN B 95 LYS B 99 -1 O LYS B 99 N CME B 88 SHEET 10 AA310 GLU B 105 PRO B 109 -1 O PHE B 108 N LEU B 96 LINK C GLU A 15 N CME A 16 1555 1555 1.33 LINK C CME A 16 N LEU A 17 1555 1555 1.32 LINK C LEU A 41 N CME A 42 1555 1555 1.33 LINK C CME A 42 N LEU A 43 1555 1555 1.33 LINK C VAL A 59 N CME A 60 1555 1555 1.33 LINK C CME A 60 N ASN A 61 1555 1555 1.32 LINK C VAL A 87 N CME A 88 1555 1555 1.33 LINK C CME A 88 N ILE A 89 1555 1555 1.33 LINK C LYS A 129 N CME A 130 1555 1555 1.33 LINK C CME A 130 N VAL A 131 1555 1555 1.33 LINK C GLU B 15 N CME B 16 1555 1555 1.32 LINK C CME B 16 N LEU B 17 1555 1555 1.32 LINK C LEU B 41 N CME B 42 1555 1555 1.33 LINK C CME B 42 N LEU B 43 1555 1555 1.33 LINK C VAL B 59 N CME B 60 1555 1555 1.33 LINK C CME B 60 N ASN B 61 1555 1555 1.32 LINK C VAL B 87 N CME B 88 1555 1555 1.34 LINK C CME B 88 N ILE B 89 1555 1555 1.33 LINK C LYS B 129 N CME B 130 1555 1555 1.34 LINK C CME B 130 N VAL B 131 1555 1555 1.33 SITE 1 AC1 14 SER A 29 VAL A 31 HIS A 44 ASN A 46 SITE 2 AC1 14 ARG A 48 HIS A 52 ASN A 61 GLU A 71 SITE 3 AC1 14 ARG A 73 ASP A 123 GLY A 124 HOH A 316 SITE 4 AC1 14 THR B 70 HOH B 327 SITE 1 AC2 12 GLN A 72 SER B 29 VAL B 31 HIS B 44 SITE 2 AC2 12 ASN B 46 ARG B 48 ASN B 61 GLU B 71 SITE 3 AC2 12 ARG B 73 ASP B 123 GLY B 124 HOH B 324 CRYST1 44.447 58.689 112.353 90.00 90.00 90.00 P 21 21 21 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.022499 0.000000 0.000000 0.00000 SCALE2 0.000000 0.017039 0.000000 0.00000 SCALE3 0.000000 0.000000 0.008901 0.00000